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Microvascular endothelial injury and dysfunction during isch- genesis of ischemic ARF. Emphasis has been placed on
emic acute renal failure. The pathophysiology of ischemic acute tubular epithelial cell injury during and immediately fol-
renal failure (ARF) appears to involve a complex interplay lowing the ischemic event. Events occurring at the cellu-between renal hemodynamics, tubular injury, and inflamma-
lar level have been identified and a much more completetory processes. While the current paradigm of the pathophysiol-
understanding of how these cellular events result in cellu-ogy of ischemic ARF invokes both sublethal and lethal tubular
injury as being of paramount importance to diminished renal lar and organ dysfunction has been established. Although
function, a growing body of evidence supports the contribution the renal tubular epithelial cell injury that initially occurs
of altered renal vascular function in potentially initiating and
during an ischemic event undoubtedly plays a centralsubsequently extending the initial tubular injury. We propose
role in ischemic ARF, there is growing evidence thatthat the “extension phase” of ischemic ARF involves altera-
tions in renal perfusion, continued hypoxia, and inflammatory additional mechanisms, including renal vascular endo-
processes that all contribute to continued tubular cell injury. thelial (VE) injury and dysfunction, play an important
Vascular endothelial cell injury and dysfunction play a vital part part in extending renal tubular epithelial injury and thusin this extension phase. In the constitutive state the endothelium
contribute to the ongoing pathogenesis of ischemic ARF.regulates migration of inflammatory cells into tissue, vascular
Therefore, we propose the addition of an “extensiontone and perfusion, vasopermeability, and prevents coagula-
tion. Upon injury, the endothelial cell loses its ability to regu- phase” to the current paradigm of ischemic ARF during
late these functions. This loss of regulatory function can have which renal VE injury and dysfunction play an important
a subsequent detrimental impact upon renal function. Vascular role. The contribution that VE injury and dysfunctioncongestion, edema formation, diminished blood flow, and infil-
make to the functional derangements observed duringtration of inflammatory cells have been documented in the corti-
and following ischemic injury in other organ systems hascomedullary junction of the kidney, but linking their genesis to
vascular endothelial injury and dysfunction has been difficult. become increasingly appreciated [1–3]. Differences may
However, new investigative approaches, including multiphoton very well exist between endothelial cells in vascular beds
microscopy and the Tie2-GFP mouse, have been developed
of different organs as well as in different vascular bedsthat will further our understanding of the roles endothelial
of the same organ [4]. However, we feel that data frominjury and dysfunction play in the pathophysiology of ischemic
ARF. This knowledge should provide new diagnostic and ther- other organs in conjunction with what sparse information
apeutic approaches to ischemic ARF. exists regarding alterations in the renal vasculature dur-
ing ischemic ARF now indicate it is time to reevaluate
the potential role that immediate and delayed injury to
Renal ischemia is the leading cause of acute renal failure endothelial cells during and following ischemic injury
(ARF) and delayed graft function. Over the past 10 to plays in the pathophysiology of ischemic ARF. There-
15 years, important advances have been made in estab- fore, the purpose of this review is to summarize what is
lishing the roles that altered vascular reactivity, tubular known about endothelial injury/dysfunction during and
epithelial cell injury, and inflammation play in the patho- following ischemia in the kidney, to present data on
endothelial injury and dysfunction during ischemia from
other organs in an attempt to infer possibilities for theKey words: endothelium, acute renal failure, ischemia, kidney disease,
inflammation, coagulation. role of the endothelium in ischemic ARF, to place these
data into a unifying hypothesis regarding immediate and
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cate how therapy of ARF should take into account the cells and renal vascular endothelial cells to maintain nor-
mal renal function. Additionally, ischemic injury to vas-pathophysiology of endothelial dysfunction.
cular smooth muscles cells and endothelial cells during
the initiation phase may contribute to the structural ab-
VASCULAR ENDOTHELIUM AS AN ORGAN normalities observed in the renal vasculature during isch-
Endothelial cells form an essentially contiguous bar- emic ARF [10–12].
rier throughout the vessels that course through every Recent evidence now indicates that “activation” of
organ. The endothelium exercises a variety of very spe- epithelial and possibly endothelial cells during the early
cific tasks and insomuch functions as a highly specialized initiation phase results in the up-regulation of a variety
organ. The concept of the endothelium as an organ has of chemokines and cytokines including but not limited to
become more widely appreciated [5, 6] given the recent interleukin (IL)-1, IL-6, IL-8, monocyte chemoattractant
recognition of the consequences of endothelial injury protein-1 (MCP-1), and tumor necrosis factor- (TNF-)
and dysfunction in a range of disease states such as sepsis, [13, 14], which are instrumental in initiating the inflam-
hemolytic uremic syndrome (HUS)/thrombotic throm- matory cascade. For example, early up-regulation and
bocytopenic purpura (TTP), diabetes, and hypertension. release of TNF- and activation of nuclear factor-B
The vascular endothelium regulates vascular permeabil- (NF-B) has been observed in an animal model of renal
ity and modulates vasomotor, inflammatory, and hemo- ischemic injury [15]. The cellular localization of these
static responses. Impairment of these vital endothelial phenomena within the kidney is just beginning to be
cell functions during and following renal ischemia can elucidated [16]. As these and other events resulting in
contribute to the impairment of renal perfusion, contin- cellular alterations are not well identified morphologi-
ued renal hypoxia, and the subsequent epithelial cell cally, they have been difficult to evaluate using standard
injury and diminution in the glomerular filtration rate methodologies. Therefore, what role these early cellular
(GFR) that are the hallmarks of ARF. responses play in further worsening renal perfusion re-
mains to be determined.
Extension phase. The proposed “extension phase” is
CLINICAL PHASES OF ACUTE RENAL FAILURE
ushered in by two major events: continued hypoxia fol-
Clinically, ischemic ARF has classically been divided lowing the initial ischemic event and an inflammatory
into the “Initiation,” “Maintenance” and “Recovery” response. Both events are more pronounced in the corti-
phases. To this paradigm we would like to add an “Exten- comedullary junction (CMJ), or outer medullary region,
sion” phase; this article explains the importance of this of the kidney. Documentation of severely reduced blood
phase in the pathophysiology of ARF and how ischemic flow, stasis and accumulation of red and white blood cells
ARF should be approached clinically. Recent studies (RBC, WBC) has been historically noted; however, the
now allow a direct relationship to be drawn between the epithelial ramifications of these events have only recently
clinical phases and the cellular phases of ischemic ARF been uncovered [13, 17]. It is during this phase that renal
(Fig. 1). Prerenal azotemia, which often precedes the vascular endothelial cell damage likely plays a key role
initiation of ischemic ARF and may be part of a contin- in the continued ischemia of the renal tubular epithelium
uum with the “initiation phase” of ischemic ARF, occurs as well as the inflammatory response observed with isch-
with reduced renal blood flow (RBF) and is associated emic ARF. During this phase cells continue to undergo
with reduced organ function (decreased GFR). Cellular injury and death, with both necrosis and apoptosis being
integrity is maintained during prerenal azotemia through present predominantly in the outer medulla [18]. In con-
vascular and cellular adaptive responses. trast, the proximal tubule cells in the outer cortex, where
Initiation phase. The “initiation phase” of ischemic blood flow has returned to near normal levels, actually
ARF occurs when RBF decreases to a level resulting in undergo cellular repair and improve morphologically
severe cellular adenosine 5-triphosphate (ATP) deple- during this phase. As cellular injury continues in the CMJ
tion, which in turn leads to acute cell injury and dysfunc- region during the extension phase, the GFR continues to
tion. Renal tubular epithelial cell injury is a key feature fall. There is continued production and release of chemo-
of the initiation phase. Renal ischemia in vivo rapidly kines and cytokines that further enhance the inflamma-
induces a number of structural and functional alterations tory cascade. Interrupting the amplification of this in-
in renal proximal tubular epithelial cells that are directly flammatory cascade may have therapeutic implications.
related spatially and temporally with disruption of the For example, inhibition of TNF- has been shown to
normal framework of filamentous actin (F-actin) in the limit the decrease in GFR occurring in the renal artery
cell [7–9]. The extent of these alterations depends upon clamp model [19]. Although the extension phase is prob-
the severity and duration of ischemic injury. Although ably the most likely phase for therapeutic intervention
these alterations usually fall short of being lethal to the in ischemic ARF, there is a short therapeutic window of
opportunity. Based on animal models of renal ischemia,cell, they do disrupt the ability of renal tubular epithelial
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Fig. 1. Relationship between the clinical phases and the cellular phases of ischemic acute renal failure (ARF), and the temporal impact on organ
function as represented by the glomerular filtration rate (GFR). Prerenal azotemia exists when a reduction in renal blood flow causes a reduction
in GFR. A variety of cellular and vascular adaptations maintain renal epithelial cell integrity during this phase. The initiation phase occurs when
a further reduction in renal blood flow results in cellular injury, particularly the renal tubular epithelial cells, and a continued decline in GFR.
Vascular and inflammatory processes that contribute to further cell injury and a further decline in GFR usher in the proposed extension phase.
During the maintenance phase, GFR reaches a stable nadir as cellular repair processes are initiated in order to maintain and re-establish organ
integrity. The recovery phase is marked by a return of normal cell and organ function that results in an improvement in GFR.
inflammatory cell infiltration in the outer medullary re-
gion of the kidney is significant by 24 hours following
ischemia [20–22], although leukocytes may begin to migrate
in as early as two hours after ischemia [23]. Figure 2
summarizes the proposed cellular interplay involved in
the pathophysiology of the initiation and extension
phases during ischemic ARF.
Maintenance and recovery phases. During the clinical
phase known as “maintenance,” cells undergo repair,
migration, apoptosis and proliferation in an attempt to
re-establish and maintain cellular and tubule integrity.
The GFR is stable albeit at a level determined by the
severity of the initial event. This cellular repair and re-
organization phase results in slowly improving cellular
function and sets the stage for improvement in organ
Fig. 3. Localization of vascular endothelium in the Tie2-GFP mouse.
Confocal image of the corticomedullary region of the mouse kidney. The
GFP-labeled endothelium of the microvasculature is easily identifiable
(arrowhead). Sections were also stained with rhodamine-phalloidin to
label actin structures (red).
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Fig. 2. Early events in ischemic ARF. The
initial ischemic insult results in morphological
and functional alterations in the renal tubules
and the renal vasculature. Following the initial
ischemic insult, further alterations in the renal
vascular endothelium of the cortico-medullary
junction contribute to inflammation and vas-
cular congestion. These processes are pro-
posed to extend the initial injury to the renal
tubules.
function. Blood flow returns toward normal and epithe- sion following ischemic injury are incompletely under-
stood. An imbalance between mediators of renal vaso-lial cells establish intracellular and intercellular homeo-
constriction and renal vasodilation has been proposedstasis. During the “recovery phase” cellular differentia-
to play a role in animal models of ischemic ARF. Intion continues, epithelial polarity is re-established, and
support of this observation, antagonists to endogenousnormal cellular and organ function returns [8, 24, 25].
vasoconstrictors have been shown to ameliorate renalThus, renal function can be directly related to the cycle
ischemic injury in animal models [31–34]. The role vari-of cell injury and recovery. There is very little known
ous vasoreactive mediators may play in controlling renalabout endothelial cell events during these two phases.
vascular tone following ischemic injury has been the sub-However, from studies in other organs, repair of the
ject of a recent review [35].endothelium is of key importance to overall recovery.
Congestion of the renal microcirculation, especially in
the peritubular capillaries of the outer medullary region
ISCHEMIC ACUTE RENAL FAILURE
(vasa recta), contributes to deficits in renal perfusion.
Alterations in renal perfusion Accumulation of red blood cells and leukocytes in the
outer medulla has been demonstrated in animal modelsA decrease in renal blood flow is of critical importance
in initiating the pathophysiology of ischemic ARF. Un- of ischemic ARF as well as in human ischemic ARF [29,
36–38]. This medullary congestion has been proposed toder physiological conditions, the oxygen tension of the
kidney decreases as one moves from the outer cortex to shunt blood flow away from the outer medulla, resulting
in continued hypoxia and cellular injury in this area.the inner medulla [26]. Interestingly, studies have pro-
vided some evidence that regional alterations in renal Experimental maneuvers to diminish trapping of red
blood cells and leukocyte attachment in the renal micro-blood flow persist after the initial ischemic event. These
regional alterations can play an important role in the circulation have been demonstrated to improve morpho-
logical and functional aspects of renal injury in animalextension phase of renal ischemic injury. During reperfu-
sion following an ischemic insult, a reduction in total models of ischemic ARF [34, 39–42].
Ischemic injury to endothelial cells and subsequent cellrenal blood flow of 40% to 50% of normal has been
reported in both animal models of ischemic ARF and swelling has been demonstrated to contribute to vascular
obstruction in other organs [43]. Given the susceptibilityin human ischemic ARF [27]. Studies have demonstrated
that a persistent reduction in renal blood flow signifi- to hypoxia in the outer medulla, endothelial ischemic
injury and cell swelling may be a plausible mechanismcantly contributes to the diminished GFR observed in
human renal allografts following ischemic ARF [28]. contributing to the congestion observed in this region.
Lastly, activation of the coagulation pathway via a dam-These persistent perfusion deficits have been demon-
strated to be of greater magnitude in the outer medulla aged endothelium may negatively impact the rheologic
properties of the blood, and play a role in stasis andthan in the outer cortex or inner medulla in an animal
model of ischemic ARF [29, 30]. decreased perfusion in the CMJ. The potential importance
of activation of the coagulation pathway in the pathogen-Mechanisms involved in the alteration of renal perfu-
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esis of ischemic ARF is highlighted by studies that dem- fluid and most solutes, recent evidence has made it appar-
ent that transcellular movement of large molecules andonstrate pretreatment with anticoagulants have a bene-
ficial effect in animal models of ischemic ARF [44–47], importantly albumin may play an important role in endo-
thelial permeability [3].although this is tempered somewhat by opposing studies
that have demonstrated no benefit [48, 49]. This differ- Specialized cellular junctions similar to those in epi-
thelial cells maintain endothelial cell-cell contacts. Cadh-ence in outcomes may reflect a more complex interplay
of the coagulation pathway with other pathways, such as erin-containing adherens junctions are ubiquitous be-
tween endothelial cells throughout the vasculature [59].the inflammatory cascade, than just serving as an isolated
thrombotic pathway. Tight junctions are more prominent in “tight” vascular
beds such as between the endothelial cells of the cerebral
Morphology of vascular injury vasculature forming the blood-brain barrier, whereas
they are sparse and simplified in “leakier” vascular bedsThe morphologic changes of the renal vasculature de-
scribed to date during ischemic ARF in animal models such as post-capillary venules of many organ vascular
beds [59]. Recent studies highlighting the differences inand in humans have been subtle and limited to the smooth
muscle layer in renal arterioles [10–12]. Interestingly, no the molecular composition of junctional complexes in
various vascular beds, including those within the kidney,consistent morphologic changes of the renal vascular
endothelium in ischemic ARF have been reported. In provide insight into the functional differences of the cel-
lular junctions in these vascular beds [60–63]. Classicpart this may be due to sampling bias in human ischemic
ARF (that is, predominantly cortical vs. medullary tissue desmosomes are not present in endothelial cells [64]. In
general, these various specialized cellular junctions areon biopsy) and difficulty in visualizing the endothelium
of potentially affected microvasculature in animal mod- not as organized spatially or morphologically in endothe-
lial cells as they are in epithelial cells. There is essentiallyels. Although no consistent morphologic alterations have
been ascribed to the endothelium of the renal vascula- no in vivo information on the effect of ischemic injury
on the function and organization of these intercellularture, evidence of endothelial dysfunction and injury in
other organ systems as a result of ischemic injury lends junctions between endothelial cells in the renal vascula-
ture. Furthermore, very few in vivo data exist on thiscredence to the concept that endothelial dysfunction and
injury play an important role in ischemic ARF [1, 50]. subject in other vascular beds. However, disruption of
endothelial adherens junctions in vivo by the use of anSeparation of endothelial tight junctions, loss of endothe-
lial attachment to the basement membrane, endothelial inhibitory antibody to VE cadherin (cadherin-5) has been
demonstrated to induce gaps between endothelial cells,blebbing, and endothelial necrosis have been described
in the cerebral and coronary vasculature following isch- increase endothelial permeability, and promote the accu-
mulation of inflammatory cells in coronary and pulmonaryemic injury [51, 52]. In patients experiencing septic shock,
a condition that shares many pathological derangements vascular beds [65]. This finding demonstrates the impor-
tance of endothelial cell-cell junctions in maintaining thewith ischemic injury [53–55] and is often a concomitant
condition in human ischemic ARF [56], detached, circu- integrity of the endothelial permeability barrier.
Much of the current knowledge regarding the mecha-lating endothelial cells have been documented [57]. Po-
tential functional consequences of these morphological nisms regulating endothelial cell-cell interaction during
ischemic and oxidant injury has come from in vitro mod-alterations include altered vascular reactivity, increased
vascular permeability, increased leukocyte adherence and els utilizing cultured endothelial cells. Increased endo-
thelial permeability and intercellular gap formation hasextravasation, and altered coagulation due to loss of nor-
mal endothelial function and/or barrier. Furthermore, been demonstrated with ATP depletion as a model of
ischemic injury and with H2O2 as a model of oxidant-circulating activated endothelial cells could potentially
contribute to distant organ effects attributed to leuko- mediated reperfusion injury [66–68]. Increased endothe-
lial permeability in these models has been associated withcytes such as pulmonary dysfunction following ischemic
ARF [58]. the redistribution of occludin and its dissociation from
zona occludens 1-antigen (ZO-1) in endothelial tight junc-
Functional aspects of endothelial injury tions as well as dissociation and internalization of VE
cadherin from endothelial adherens junctions [67, 69, 70].Alterations in endothelial permeability. Increased per-
itubular capillary permeability has been documented as There is evidence that the interaction of endothelial
cell-cell junctions with the actin cytoskeleton plays ana consequence of ischemic ARF in animal models [41].
Two general mechanisms can account for increased en- important role in regulating endothelial paracellular trans-
port. Transfection of a mutant VE cadherin lacking adothelial permeability during ischemic injury: increased
paracellular permeability and/or increased transcellular portion of the cytoplasmic domain important for binding
to -catenin and linking the adherens junction to the actinpermeability [3]. While most evidence favors increased
paracellular transport as the pathway for movement of cytoskeleton has been demonstrated to increase mono-
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layer permeability as compared to cells transfected with ing ischemia reperfusion-injury has been documented to
occur also in the absence of leukocytes [93]. Therefore,wild-type VE cadherin [71]. ATP depletion of endothelial
cell monolayers and exposure of endothelial monolayers the quantitative role of leukocytes in increasing endothe-
lial permeability remains to be determined.to oxidants such H2O2 have both been demonstrated to
alter the normal actin cytoskeleton of endothelial cells. Alterations in endothelial-leukocyte interactions. As
mentioned previously, the stasis of leukocytes observedATP depletion has been demonstrated to disrupt the
normal cortical and basal F-actin structures in endothelial in the outer renal medulla after reperfusion in human
and animal ischemic ARF can potentially extend thecells [72–74]. As has been demonstrated in renal tubular
epithelial cells during ATP depletion as well as the renal injury incurred during ischemia. In addition to physically
obstructing the renal microcirculation, activated leuko-artery clamp model, F-actin structures associated with
the surface membrane breakdown and F-actin aggregates cytes can initiate an inflammatory cascade that leads to
endothelial dysfunction and alteration of the endothelialappear dispersed throughout the cytoplasm [73]. Total
cellular F-actin content increases during ATP depletion permeability barrier. The relative roles specific leuko-
cytes play in the injury observed in models of ischemicin many cell types in cell culture studies. Oxidant-medi-
ated endothelial cell injury also has been demonstrated ARF has been a point of uncertainty. A growing body
of evidence suggests that T cells may play a pivotal partto disrupt the cortical actin band in cultured endothelial
cells [75–77]. These same studies have demonstrated an in this injury [22, 94–96], although a recent study adds to
the controversy concerning the role of T cells in ischemicincrease in basal actin stress fibers during oxidant-medi-
ated endothelial cell injury [75–77]. Interestingly, there acute renal failure [97]. Regardless of the specific leuko-
cyte type, activated leukocytes can release cytokines,is evidence suggesting that activation of endothelial con-
traction through actin stress fibers can increase endothe- proteases, and mediators of oxidant injury [88], which
likely plays an important pathophysiological role in epi-lial paracellular permeability [78, 79]. Thus, not only
can disruption of the actin cytoskeleton (especially the thelial cell injury and subsequent organ dysfunction.
Endothelial-leukocyte interactions mediated throughcortical actin band) increase endothelial paracellular
permeability, but activation of contractile force through complementary adhesion molecules on endothelial cells
and leukocytes play a key role in the local accumulationthe actin cytoskeleton (tensegrity model) [80] can also
increase endothelial paracellular permeability. of leukocytes. The selectin family of adhesion molecules
(L-selectin on leukocytes and P- and E-selectins on endo-Numerous signaling pathways have been implicated in
the regulation of the actin cytoskeleton including pathways thelial cells) and their carbohydrate-containing counter
ligands initiate intermittent, low-affinity binding (rolling)involving the Rho family GTPases, phosphoinositides, ty-
rosine kinases, protein kinase C, and cAMP-dependent between leukocytes and endothelial cells [98]. Members
of the IgG superfamily of adhesion molecules, includingprotein kinase [81–86]. The complexity and cross talk of
the signaling pathways regulating the actin cytoskeleton intercellular adhesion molecule-1 (ICAM-1) on endo-
thelial cells and their counter -integrin receptors onin endothelial cells during ischemic injury has garnered
increased appreciation in recent years. Much work is leukocytes, mediate a tighter binding that plays a role
in leukocyte extravasation [99].needed at the molecular level to elucidate the relative
contributions of the signaling pathways involved. Ischemic injury has been demonstrated to increase
expression of P- and E-selectin on the surface of endo-Increased interstitial edema may contribute to further
diminishing the compromised medullary blood flow by thelial cells [100, 101]. Rearrangements of the actin cyto-
skeleton are important in the rapid delivery of P-selectincompressing peritubular capillaries [87]. Additionally,
leakage of plasma from the vascular space through a leaky from its storage in Weibel-Palade bodies to the surface
of endothelial cells [50]. Increased expression of ICAM-1endothelium contributes to hemoconcentration that can
lead to stasis and diminished perfusion in the CMJ as by endothelial cells has been demonstrated also in vitro
in response to oxidant injury [102]. The functional sig-observed in other organs [43]. Hemoconcentration and
stasis also increases the potential for endothelial-leuko- nificance of these findings in ischemic ARF is underscored
by evidence in animal models that inhibition of P- andcyte interactions. Activated leukocytes can initiate an
inflammatory cascade that leads to further endothelial E-selectin mediated binding of leukocytes [40] and inhi-
bition of ICAM-1 mediated binding of leukocytes [20,cell injury and further dysfunction of the endothelial
permeability barrier [88]. This may be particularly im- 103] decreases renal injury. Endothelial cell injury and
dysfunction additionally may contribute to the inflam-portant in the medullary region as endothelial cells there,
but not in the cortex, express surface markers important matory response through loss of normal endothelial NO
production [17].in lymphocyte activation [89]. While the interaction of
activated leukocytes and the endothelium has been dem- Alterations in coagulation. Fibrin deposition in the mi-
crovasculature following ischemic injury has been notedonstrated to play a role in enhancing endothelial perme-
ability [90–92], increased endothelial permeability dur- in a variety of organs systems including the kidney [104–
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107]. Although the constitutive state of endothelial cells to localize the cell types involved. For example, the trans-
genic mouse developed by Motoike et al that expressesis an anticoagulant state, injury and activation of endo-
thelial cells can induce a procoagulant response. Whether the green fluorescent protein (GFP) under control of the
endothelial-specific Tie2 promoter provides a tool to iden-or not this occurs during prerenal azotemia is unknown.
As a result of endothelial injury, anticoagulant substances tify and visualize the endothelium of the renal vascula-
ture (Fig. 3) [120].such as thrombomodulin are internalized or released in an
inactive form [108]. Thrombomodulin acts as a molecular Functional imaging techniques, including spinning-
disc confocal fluorescence microscopy, 2-photon micros-switch that converts thrombin from activating procoagu-
lant pathways to preferentially activating anticoagulant copy, and blood oxygenation level-dependent (BOLD)
magnetic resonance imaging (MRI), are other potentiallypathways. Loss of membrane-bound thrombomodulin
activity promotes the local generation of fibrin by throm- powerful investigational tools that have the promise of
providing new insights into the in vivo functional alter-bin and diminishes activation of protein C by thrombin
[109]. Diminished activated protein C (aPC) results in ations that occur during ischemic renal injury [121, 122].
For example, BOLD MRI is a noninvasive techniquethe decreased formation of protein C/protein S complexes
thus reducing the inactivation of factors Va and VIIIa that takes advantage of the capacity of deoxyhemoglobin
to act as an endogenous contrast agent. This techniqueand further promoting local thrombin generation [110].
The net result is a shift in the balance toward a procoagu- has been utilized to examine regional alterations in oxy-
genation of the kidney in response to various physiologi-lant response. As a result of endothelial cell injury, the
profibrinolytic properties of the endothelial cell are also cal and pathophysiological perturbations such as diuretic
and intravenous radiocontrast administration [123–125].diminished. Loss of tissue plasminogen-activator (tPA)
secretion by the injured endothelium, release of plasmin- Recent advances made toward delineating the cellular
mechanisms involved in ischemic ARF have not yet led toogen-activator inhibitor (PAI) from localized inflamma-
tory cells [111] that can inhibit what little tPA is released, accepted therapeutic interventions that alter the natural
course of ARF or improve the clinical outcome for ARF.and loss of activated protein C inhibition of thrombin-
Overall mortality for ARF remains between 40 and 50%activatable fibrinolysis inhibitor (TAFI) [109] can all con-
in a general series of patients and 70 and 80% for patientstribute to diminished fibrinolysis. Furthermore, loss of
in intensive care units [126]. Moreover, 1 to 2% of allNO production by injured endothelial cells also may con-
patients and 30% of patients in the intensive care unittribute to an overall procoagulant state through loss of its
who survive an episode of ARF requiring dialytic ther-inhibitory role on cytokine-induced expression of tissue
apy become dependent on long-term dialysis or renalfactor [112]. While abnormalities in coagulation per se
transplantation [126, 127]. Some excellent reviews thatmay have a deleterious role in ischemic ARF, recent stud-
outline potential therapeutic strategies for the treatmenties have shed light on the relative importance the coagu-
of ARF and that detail some of the barriers that needlation cascade plays as a mediator of inflammation in
to be overcome in bringing effective therapies to fruitionischemic ARF [47, 113].
have been recently published [14, 88]. Needless to say,
human ARF is heterogeneous in its pathophysiology.
FUTURE DIRECTIONS AIMED AT THE Consequently, combined therapies targeting more than
EXTENSION PHASE one pathophysiological pathway may prove to be the
As mentioned previously, investigating the role that most beneficial approach [14, 88]. It is also necessary to
alterations in the renal vasculature play in the pathophys- point out that differences exist between animal models
iology of ischemic renal injury during the extension phase of ARF and what has been documented to occur during
has been difficult. Fortunately, new tools may provide human ARF. These differences and similarities have
avenues of fruitful investigation into this area. Spatially been recently discussed in two reviews and are beyond
localized genomic approaches including direct in situ re- our scope [128, 129]. However, a major problem is the
verse transcription-polymerase chain reaction (RT-PCR) lack of clinical data, especially in the cortical-medullary
assays or real time PCR assays coupled with laser-cap- junctional area, during the early phases—initiation and
ture microdissection have the potential to provide new extension—of human ARF.
insight into the complexity of gene expression in the renal Therapies directed at processes during the extension
vasculature during injury and recovery [114–117]. Simi- phase including endothelial dysfunction/injury and its
larly, progress in proteomics may provide powerful and myriad of pathophysiological implications will have a role
complimentary information to genomic approaches [118, in this therapeutic approach. Promising approaches in-
119]. Functional deletion of proteins in a tissue specific clude targeting endothelial injury with agents such as leci-
manner or exploitation of tissue specific promoters may thinized superoxide dismutase [130], targeting endothelial
further our understanding of the mechanisms involved activation of the coagulation cascade with agents such as
activated protein C (APC) [113], and targeting enhancedin renal injury and repair, as well as, provide a means
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Fig. 4. Proposed contribution of vascular en-
dothelial cell injury and dysfunction to injury
during ischemic ARF. Altered coagulation,
vascular tone, vasopermeability, and regulation
of inflammatory cell adhesion and migration
into tissue as a result of endothelial cell injury
and dysfunction during ischemic ARF may
contribute to continued hypoxia and inflam-
mation especially in the corticomedullary re-
gion. Consequently, endothelial cell injury is
proposed to extend the initial ischemic injury
to the tubular epithelial cells in this region.
endothelial-leukocyte interactions with agents such as and extension phases. Further investigation into the
mechanisms of endothelial injury and dysfunction duringanti-B7-1 [95], anti-ICAM-1 antibodies [20], P-selectin
antagonists [40], platelet activating factor (PAF) antago- the extension phase should provide more insight into
the pathophysiology of ischemic ARF and reveal addi-nists [34], adenosine 2A receptor agonists, phosphodies-
tional as well as novel therapeutic interventions.terase type IV antagonists [131], and TNF- binding
protein [19]. This list is not meant to categorize these
biomolecules into one particular mode of action as it NOTE ADDED IN PROOF
clear that some have an impact on more than one patho-
Since acceptance of this manuscript in final form, im-physiological pathway. For example, the beneficial effect
portant articles by Yamamoto et al (Am J Physiol Renalof APC may be the result of its anti-inflammatory prop-
Physiol 282:F1150–F1155, 2002) and Brodsky et al (Amerties more than its anticoagulant or fibrinolytic proper-
J Physiol Renal Physiol 282:F1140–F1149, 2002) have beenties [113]. Furthermore, if vector technology can reliably
published that give further evidence for the importancetraverse the glomerular capillary network, the endothe-
of vascular and endothelial dysfunction/injury in thelium of the CMJ would be an accessible target for gene
pathophysiology of ischemic acute renal failure.therapy. Although early recognition of renal injury and
prompt intervention remain to be clinical challenges in
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